Erin is currently the Program Clinical Scientist in Global Clinical Trial Operations at Merck for verubecestat, which is a BACE Inhibitor that is in late-stage development for the treatment of Alzheimer’s disease, with two ongoing global Phase 3 clinical trials.

Prior to rejoining Merck in 2016, Erin was the Phase 3 Program Lead for aducanumab, which is a monoclonal antibody that is being developed by Biogen, where she was responsible for the start-up and execution of this global Phase 3 program which is under investigation for the treatment of early Alzheimer’s disease.

Erin’s earlier tenure at Merck began in 2004, where she held various roles of increasing responsibility which included Protocol Lead Clinical Research Specialist and Program Lead Clinical Scientist across several disease areas including diabetes, migraine, insomnia, depression and neuropathic pain. Erin was a significant contributor to the clinical development of the Januvia™ and Janumet™ programs for Type 2 Diabetes as well as a primary author on several regulatory submission documents for Maxalt™ for pediatric migraine.

Prior to joining Merck, Erin was a Study Coordinator for the Chairman of Psychiatry at Boston University School of Medicine where she focused on addiction research.

Erin has a BA in Psychology from Eckerd College and has completed several courses towards a graduate degree in Public Health at Boston University and the University of Pennsylvania. She is a member of Drug Information Association and the Alzheimer’s Association.